Goy Shares Insights on Acalabrutinib and Ibrutinib Data in MCL

The field of mantle cell lymphoma underwent a significant change with the FDA approval of ibrutinib (Imbruvica) in 2013. Now, the recent approval of acalabrutinib (Calquence) has similarly impacted the treatment landscape, as experts say it could be associated with slightly fewer adverse events than ibrutinib, according to Andre Goy, M.D.

Read full article on